期刊文献+

白细胞淤滞分级评分在高白细胞急性髓系白血病降白细胞治疗效果评估中的应用 被引量:2

Application of leukostasis grading score system to evaluate the efficacy of leukocyte reduction in hyperleukocytic acute myeloid leukemia
原文传递
导出
摘要 目的应用白细胞淤滞分级评分(LGS)评价高白细胞急性髓系白血病(HAML)降白细胞的疗效。方法回顾性分析54例HAML患者临床资料,根据患者临床症状和LGS系统进行评分,分析LGS与患者白细胞淤滞症状和早期病死率的关系,并分析降白细胞治疗后LGS变化。结果54例HAML患者中M1 1例,M2 16例,M4 10例,M5 20例,未分型7例。LGS0分3例,LGS1分15例,LGS2分17例,LGS3分19例。LGS≤2分患者中自细胞淤滞所致的I型呼吸衰竭、中枢神经系统症状及早期病死的发生率均低于LGS3分的患者(P〈0.05)。降白细胞治疗后HAML患者LGS较治疗前改善(P〈0.0001)。其中降白细胞治疗过程中白细胞分离组LGS改善率高于未分离组(P=0.008)。37例患者接受诱导化疗,1个周期化疗后20例获得完全缓解,LGS≤2分患者完全缓解率与LGS3分者差异无统计学意义(P=0.703)。结论LGS能够反映HAML患者白细胞淤滞的程度,可以评价降白细胞治疗后白细胞淤滞改善情况,LGS高预示更高的早期病死率。白细胞分离术联合小剂量化疗较单纯小剂量化疗能显著降低LGS。 Objective To evaluate the treatment efficacy of leukocyte reduction in hyperleukocytic acute myeloid leukemia (HAML) patients with leukostasis grading score (LGS). Methods The data of 54 HAML patients were analyzed retrospectively. The relationship between LGS and leukocyte stasis symptoms or early mortality was observed, and the impact of leukapheresis on LGS was analyzed. Results Among 54 patients with HAML, there were 1 case of M1, 16 cases of M2, 10 cases of M4, 20 cases of M5 and 7 cases of unclassified AML. Based on clinical symptoms and LGS system, 3 cases were LGS 0, 15 cases LGS 1, 17 cases LGS 2, and 19 cases LGS 3. In patients with LGS ~〈 2, the rates of type I respiratory failure, central nevers system (CNS) symptoms and early mortality caused by leukostasis were significantly lower than those in patients with LGS 3 (P 〈 0.05). The LGS of HAML patients was reduced by leukocyte reduction therapy (P 〈 0.000 1). The LGS of HAML patients treated by leukapheresis and low dose chemotherapy was improved significantly than that of patients treated without leukapheresis (P = 0.008). Among 37 cases receiving induction chemotherapy, 20 cases reached complete remission (CR) after the first cycle of induction chemotherapy. CR rate of patients with LGS ~〈 2 was no significantly different compared with that of patients with LGS 3 (P = 0.703). Conclusions LGS can be used to evaluate the degree and the improvement status of leukostasis after treatment in HAML patients. The early death often oceurres in patients with high LGS. Leukapheresis combined with low-dose chemotherapy can effectively improve the LGS of HAML patients.
出处 《白血病.淋巴瘤》 CAS 2015年第12期729-731,739,共4页 Journal of Leukemia & Lymphoma
基金 首都医学发展科研基金(2009-3192) “215”高层次卫生技术人才培养计划一学科骨干项目(2013-3-097)
关键词 白血病 髓样 急性 白细胞淤滞分级评分 Leukemia, myeloid, acute Leukostasis grading score
  • 相关文献

参考文献9

  • 1Novotny JR, Müller-Beissenhirtz H, Herget-Rosenthal S, et al. Grading of symptoms in hyperleukocytic leukaemia: a clinical model for the role of different blast types and promyelocytes in the development of leukostasis syndrome[J]. Eur J Haematol, 2005, 74(6): 501-510.
  • 2Ganzel C, Becker J, Mintz PD, et al. Hyperleukocytosis, leukostasis and leukapheresis: practice management[J]. Blood Rev, 2012, 26(3): 117-122.
  • 3Piccirillo N, Laurenti L, Chiusolo P, et al. Reliability of leukostasis grading score to identify patients with high-risk hyperleukocytosis[J]. Am J Hematol, 2009, 84(6): 381-382.
  • 4H?觟liga K, Moog R. Leukocyte depletion by therapeutic leukocytapheresis in patients with leukemia[J]. Transfus Med Hemother, 2012, 39(4): 241-245.
  • 5Zuckerman T, Ganzel C, Tallman MS, et al. How I treat hematologic emergencies in adults with acute leukemia[J]. Blood, 2012, 120(10): 1993-2002.
  • 6Schwartz J, Winters JL, Padmanabhan A, et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the writing committee of the American Society for apheresis: the sixth special issue[J]. J Clin Apher, 2013, 28(3): 145-284.
  • 7De Santis GC, de Oliveira LC, Romano LG, et al. Therapeutic leukapheresis in patients with leukostasis secondary to acute myelogenous leukemia[J]. J Clin Apher, 2011, 26(4): 181-185.
  • 8Oberoi S, Lehrnbecher T, Phillips B, et al. Leukapheresis and low-dose chemotherapy do not reduce early mortality in acute myeloid leukemia hyperleukocytosis: a systematic review and meta-analysis[J]. Leuk Res, 2014, 38(4): 460-468.
  • 9李天乐,江雪杰,王治香,张灵秀,钟清秀,孟凡义.高白细胞急性髓系白血病100例早期合并症分析及其干预方法优化[J].实用医学杂志,2013,29(15):2537-2539. 被引量:5

二级参考文献15

  • 1张之南.血液病诊断及疗效标准[M].3版.北京:科学出版社,2008:1.
  • 2Porcu P, Cripe L D, Ng E W, et al. Hypedeukocytic leukemias and leukostasis: a review of pathophysiology, clinical presentation and management [J]. Leuk Lymphoma, 2000,39(1-2) .. 1-18.
  • 3Ganzel C, Becket J, Mintz P D, et al. Hypedeukocytosis,leukostasis and leukapheresis: Practice management [J]. Blood Rev, 2012,26(3) : 117-122.
  • 4Novotny J R, Muller-Beissenhirtz H, Herget-Rosenthal S, et al. Grading of symptoms in hyperleukocytic leukaemia: a clinical model for the role of different blast types and promyelocytes in the development of leukostasis syndrome [J]. Eur J Haematol, 2005,74(6) : 501-510.
  • 5Cairo M S, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification [J ]. Br J Haematol, 2004,127(1) :3-11.
  • 6Org N. Acute Myeloid Leukemia, NCCN clinical praetiee guidelines in oneology. Version 2.2011 [M]. 2010.
  • 7Marbello L, Ricci F, Nosari A M, et al. Outcome of hyperleukocytic adult acute myeloid leukaemia: a single-center retrospective study and review of literature [J]. Leuk Res, 2008,32 ( 8 ) : 1221-1227.
  • 8Kedar A, Grow W, Neiberger R E. Clinical versus laboratory tumor lysis syndrome in children with acute leukemia [J]. Pediatr Hematol Oncol, 1995,12 ( 2 ) : 129-134.
  • 9Montesinos P, Lorenzo I, Martin G, et al. Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model [ J ]. Haematologica, 2008,93 ( 1 ) : 67-74.
  • 10Abu-Alfa A K, Younes A. Tumor lysis syndrome and acute kidney injury: evaluation, prevention, and management [J]. Am J Kidney Dis, 2010,55(5 Suppl 3):S1-S13, S14-S19.

共引文献4

同被引文献9

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部